🇺🇸 FDA
Patent

US 12419870

Compositions and methods for immune cell modulation in adoptive immunotherapies

granted A61KA61K2239/31A61K2239/38

Quick answer

US patent 12419870 (Compositions and methods for immune cell modulation in adoptive immunotherapies) held by Fate Therapeutics, Inc. expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Fate Therapeutics, Inc.
Grant date
Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2239/31, A61K2239/38, A61K31/436, A61K35/28